Chiasma is a biopharmaceutical company developing oral drugs that were previously only available by injection, providing patients with pain-free medications that are self-administered. In June 2015, the company submitted a New Drug Application to the US FDA seeking approval of its lead product, oral octreotide capsules, for the maintenance treatment of adults with acromegaly. Chiasma went public in July 2015.

Location New York and Jerusalem, Israel
CEO Mark Fitzpatrick
Partner Vincent Miles
Website http://www.chiasmapharma.com/